Table 3.
B12 and FA levels in the disease characteristics of the CD group.
| n (%) | B12 Median (IQR) |
FA Median (IQR) |
|
|---|---|---|---|
| CDAI | |||
| Inactive | 63 (61.2%) | 167 (136–208) | 4.6 (4–5.6) |
| Mild | 24 (23.3%) | 125 (99.75–168.5) | 5 (4.125–5.675) |
| Moderate | 16 (15.5%) | 120 (87–126.25) | 4.6 (3.25–5.725) |
| P * | <.001 | .729 | |
| Duration of disease | |||
| 0–5 yr | 31 (30.1%) | 154 (120–189) | 4.6 (4–5.8) |
| 6–10 yr | 25 (24.3%) | 162 (121–209) | 4.5 (4.05–5.45) |
| >10 | 47 (45.6%) | 161 (120–181) | 4.5 (4–5.6) |
| P * | .554 | .952 | |
| Montreal classification | |||
| A1 | 4 (3.9%) | 142.5 (122.5–226.25) | 6 (3.85–7.025) |
| A2 | 59 (57.3%) | 157 (120–184) | 4.5 (4.3–5.6) |
| A3 | 40 (38.8%) | 163 (120.75–185) | 4.6 (4.3–5.6) |
| P * | .809 | .138 | |
| L1 | 51 (49.5%) | 124 (99–161) | 4.6 (4–5.4) |
| L2 | 12 (11.7%) | 163.5 (111.5–202.75) | 4.3 (4–4.725) |
| L3 | 40 (38.8%) | 176 (162.5–207.75) | 4.8 (4.2–5.975) |
| P * | <.001 | .319 | |
| B1 | 67 (65%) | 162 (122–194) | 4.5 (4–5.6) |
| B2 | 18 (17.5%) | 144.5 (117.7–195.75) | 4.7 (3.95–5.4) |
| B3 | 13 (12.6%) | 165 (111–180) | 5.2 (4.45–6.1) |
| Perineal disease | 5 (4.9%) | 125 (103.5–143) | 5 (4–7.05) |
| P * | .35 | .459 | |
| Resection | |||
| Yes | 31 (30.1%) | 157 (119–185) | 5 (4–5.8) |
| No | 72 (69.9%) | 162 (120.5–185) | 4.55 (4–5.6) |
| P * | .386 | .708 | |
| 5-ASA | |||
| Yes | 52 (50.5%) | 161 (121.5–184.2) | 4.3 (4–5.175) |
| No | 51 (49.5%) | 161 (120–201) | 5.2 (4.25–5.85) |
| P * | .797 | .02 | |
| AZA | |||
| Yes | 28 (27.2%) | 150 (119–187) | 5.1 (4.3–5.8) |
| No | 75 (72.8%) | 161.5 (122–185) | 4.3 (4–5.375) |
| P * | 0.642 | 0.052 | |
| Biologic agents | |||
| Yes | 6 (5.8%) | 174.5 (161.7–220.7) | 5.1 (4.175–6.2) |
| No | 97 (94.2%) | 150 (119.5–179.5) | 4.5 (4–5.55) |
| P * | 0.01 | 0.203 | |
| Sulfasalazin | |||
| Yes** | 2 (1.9%) | 219 (120–314) | 5.3 (5.3–6) |
| No | 101 (98.1%) | 161 (120–184.75) | 4.55 (4–5.6) |
| P * |
ASA = 5-aminosalicylic acid, AZA = azathioprine, CD = Crohn’s disease, CDAI = Crohn’s disease activity index.
*
CDAI Inactive vs mild L2 P = .001 Inactive vs moderate L3 P < .001 mild vs moderate P = .214 Localization L1 vs L2 P = .089 L1 vs L3 P < .001 L2 vs L3 P = .152.
**
Insufficient sample excluded from the analysis.